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’INTRODUCTION
Ion channels are integral membrane proteins that govern the
passage of ions across cell membranes. Encoded by approxi-
mately 400 ion channel genes in the human genome, this super-
family of membrane proteins is involved in many important
physiological functions such as the regulation of blood pressure,
neurotransmission, and hormonal secretion.
1,2 Ion channels are
implicated in a wide range of diseases including hypertension,
neuromusculardisordersandParkinson’sdisease.Consequently,
they constitute the third largest class of targets in drug discovery
afterproteinkinasesandG-proteincoupledreceptors.
2,3Despite
its wide implication in disease conditions, the development of
drugstargetingthismembrane protein superfamilyhasremained
underexploited, with only about 10% of drugs on the current
market known to bind to ion channels.
1,4
Since the advent of high-throughput screening (HTS) for
drug discovery in the 1980s, HTS has become an important tool
forhitidentiﬁcationinpharmaceuticalresearch.Inthepastdecade,
strategies have evolved from traditional diverse HTS to the
screening of focused libraries for a particular class of biological
targets.
57 For example, protein kinase-focused screening
libraries have been reported by us and other research groups
using well-documented structural motifs to select compounds
satisfying a deﬁned pharmacophore.
8,9 However, in comparison
to protein kinases, the assembly of a focused screening library
targeting ion channels is more challenging owing to limited
structuralinformationaboutthetargets,theirstructuraldiversity,
and the absence of well-deﬁned pharmacophores required for
binding to ion channels.
10
The release of the ChEMBL database
11 has facilitated open-
access to a large volume of small-molecule bioactivity data for
various therapeutic target families, including ion channels. Here,
wedescribeaneﬃcientworkﬂowforcompilingafocusedscreen-
ing libraryfor ionchannel targetsusinga combination ofdatabase
mining and various chemoinformatics analytical tools for struc-
tural class generation and compound selection. The established
workﬂow can easily be adopted to assemble focused screening
libraries for other therapeutic target classes with diverse recogni-
tion motifs.
’RESULTS
To enable an eﬃcient assembly of the ion channel-focused
screening library, the procedure was divided into ﬁve stages
(Figure 1).
Data Retrieval and Analysis. Bioactivity data of compounds
active against ion channel targets were retrieved from the
ChEMBL database.
11 This data set (ChEMBLinitial data set)
contained 25150 compounds reported to be active against 337
differentmoleculartargets. Thesecompoundsweresubsequently
groupedunder14ionchannelcategories(Figure2).Themajority
of the classification of ion channel categories followed those as
defined in ChEMBL, apart from the groups of ligand- (LGIC)
and voltage-gated ion channels (VGC) which were further divi-
ded to facilitate data handling. For LGIC, individual categories
were constructed for glutamate-activated receptors and purino-
ceptors. Acetylcholine and serotoninergic 5HT3 receptors were
grouped together to form the cationic Cys-loop channels
(CationicCysLoop),whereasGABAAandglycinereceptorswere
categorizedasanionicCys-loopchannels(AnionicCysLoop).For
VGC, each of sodium (Na
+), calcium (Ca
2+), potassium (K
+),
and cGMP-gated channels formed individual categories. The
viralcategorywasexcludedastherewasnobioactivecompounds
reported.
Various ﬁlters were applied to the ChEMBLinitial data set for
theselectionofcompoundstoformtheChEMBLﬁltereddataset
(Figure 3). First, ﬁlters were introduced to exclude compounds
for which bioactivity data was reported only for species other
thanrat,mouseorhuman.Next,theChEMBLconﬁdencescores
forallbioactivitydatawerecheckedtoensuretherewasnoexperi-
mental data representing activity against nonmolecular or non-
protein targets (ChEMBL conﬁdence score between 1 and 3
inclusive).Asexpected,nocompoundswereremovedas aresult.
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Further,onlycompoundswithreportedbioactivity(Ki,K d,IC 50,
or EC50)o fe10 μM were kept. Compounds were then ﬁltered
using a molecular weight cutoﬀ of 600 Da. Although this cutoﬀ
value would allow compounds that violate Lipinski’s rule-of-
ﬁve,
12 it was considered appropriate at this stage of the analysis
to minimize loss of core structural information when generating
structuralclasses(seebelow).Finally,compoundscontainingun-
wanted groups
8 were excluded. This led to a collection of 7102
compounds representing 10 ion channel categories (Figure 2).
Structural Class Generation. Commercial availability search
for compounds of the ChEMBLfiltered data set using our in-house
database
8revealedonly329availablecompounds.Inlightofthis,
bioactivetemplatesrepresentingthedifferentstructuralclassesof
ionchannelmodulatorsweregeneratedforsubsequentsubstruc-
ture searches. Bioactive templates were identified by searching
formaximumcommonsubstructures(MCS)ofcompoundswithin
eachionchannelcategoryintheChEMBLfiltereddataset.During
thisprocess,singletonsandunder-representedclasses(seeExperi-
mental Procedures) were excluded. Afterward, the structures of
the bioactive templates were visually inspected, and any synthe-
tically intractable structures were rejected to avoid the presence
of synthetically challenging compounds in the final screening
librarythatwouldnotbeproceededashitorleadcandidates.307
bioactivetemplatesoutof548generatedtemplateswereselected
in the final collection and annotated against their respective
categories of ion channels (Table 1).
Commercial Availability Search. After merging identical
templates present in multiple categories, 297 unique bioactive
templates were used as substructures to search for commercially
available lead-like compounds in our in-house database.
8
Figure 1. Workﬂow for the assembly of the ion channel-focused screening library.
Figure 2. Percentage composition per ion channel category in the ChEMBLinitial, ChEMBLﬁltered, and DDU_IC data sets. No desirable bioactive
compounds were found for four categories of ion channels (amiloride-sensitive sodium channels (ASIC), cGMP-gated channels, ryanodine receptors,
and IP3 receptors).
Figure3. CompilationoftheChEMBLﬁltereddatasetcontainingbioactiveionchannelcompounds.Numberofcompoundsretainedateachﬁlterstep
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This search identified 92340 compounds representing 149 bio-
active templates, forming the CommAvail data set which con-
tained on average ∼620 compounds per template.
Diversity Analysis and Compound Selection. To avoid
over-representation of certain templates and to keep the library
at an affordable size, a maximum of 50 compounds per bioactive
template was imposed.
8 In the 77 templates which were repre-
sented by more than50 compounds (Figure 4), molecular diver-
sityofcompoundswasanalyzedusingmolecularfingerprintsand
the 50 structurally most diverse compounds were retained in the
data set. Subsequently, the data set was visually inspected to
removeanycompoundscontainingsyntheticallyintractablestruc-
tures attached to the templates. Finally, all bioactive templates
which had five or fewer examples remaining were considered
under-represented,andthereforethesecompoundswereexcluded
from the data set.
The 3241 compounds that passed all ﬁlter steps were pur-
chasedtoformtheﬁnalfocusedscreeninglibrary(DDU_ICdata
set)(Figure2).Covering123bioactivetemplatesacrossnineion
channel categories, these compounds were annotated with their
respective ion channel category to assist back-tracing of prospec-
tive molecular targets from phenotypic screening results.
Despite the number of templates progressively decreasing
from 297 templates in the ChEMBLﬁltered data set to only
123templatesintheDDU_ICdataset,thepercentagecomposition
of each ion channel category remained approximately constant
throughout the process (Figure 5). On average, 38% of the
templates per category in ChEMBLﬁltered were represented in
DDU_IC. Out of the nine ion channel categories represented,
onlytheAnionicCysLoopcategoryshowedaconsiderablereduc-
tion, with eight out of the 36 templates (22%) in ChEMBLﬁl-
tered represented in DDU_IC. In contrast, 61% of the 34 tem-
plates for transient receptor potential channels were represented
in the ﬁnal library.
’DISCUSSION
Screening of focused libraries is considered to be a cost-
eﬀectivestrategyforhitdiscovery.
57Compilingfocusedlibraries
requires analysis of relevant chemical space in order to enrich
compounds that are likely to interact with the desired target
class.
5 This is commonly achieved by deﬁning pharmacophoric
or structural motifs satisfying speciﬁc binding interactions for
the desired target class, which consequently requires a thorough
Table 1. Number of Compounds, Bioactive Templates, and Singletons within Each Category of Ion Channels in the
ChEMBLﬁltered Data Set
ion channel category total no. of compounds total no. of templates no. of templates selected no. of singletons
AnionicCysLoop 1589 94 36 288
CationicCysLoop 1383 94 60 856
purinoceptors 14 2 2 3
glutamate 1586 106 59 368
Na
+ 326 30 17 63
Ca
2+ 437 46 21 108
K
+ 959 112 71 119
InwardlyRectifyingK
+ 51 9 3 13
transient receptor potential 671 42 34 51
sulfonylurea 86 13 4 11
total 7102 548 307 1880
Figure 4. Number of compounds per bioactive templates across diﬀerent ion channel categories in the CommAvail data set.2452 dx.doi.org/10.1021/ci200260t |J. Chem. Inf. Model. 2011, 51, 2449–2454
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understanding of the structural features and patterns of the
proteinligand interactions.
8,9 Therefore, focused library con-
struction is more challenging when the recognition motifs of the
target class are less established.
10 With the ﬁrst crystal structures
of ion channel targets just emerging
13 and due to their hetero-
geneous nature involving 16 subfamilies,
14 the assembly of
focused screening libraries for ion channels clearly represents a
demanding task.
The workﬂow described here (Figure 1) provides an eﬃcient
protocol to analyze relevant bioactive data for ion channels
and to use this information for compiling a focused library.
The ChEMBL database oﬀers direct access to chemical com-
poundsassociatedwithionchannelactivity.However,sincemost
of the compounds in ChEMBL are not commercially available,
15
theidentiﬁcationofbioactivetemplatesusingMCSrepresentsan
eﬀective method to derive substructures which can subsequently
be used to retrieve commercially available compounds that are
likely to modulate ion channel activity. In addition to improving
compound availability, these bioactive templates, unlike many
descriptorsderivedtopredictbioactivityofchemicalcompounds,
16,17
are easy tointerpret anddonotrequire expertchemoinformatics
knowledge,hencesyntheticallyintractabletemplatescanberejec-
ted at an early stage by visual inspection. Besides, this MCS
approach alsoallowsthe identiﬁcation of promiscuous templates
which appear across multiple ion channel categories. Indeed, we
identiﬁed eight bioactive templates which are common to multi-
ple ion channel categories using this workﬂow. Such observation
would have been much more diﬃcult if using more traditional
similarity-based approaches such as molecular ﬁngerprints com-
parison. However, promiscuous inhibitors
18 in ChEMBL erro-
neously reported to be active against certain targets are diﬃcult
to bedetectedusingthis workﬂow. The selected compoundscan
be annotated with the respective ion channel category they were
derived from, which facilitates target identiﬁcation when using
thelibraryforphenotypicscreening.Thisworkﬂowisnotlimited
to ion channels but can be adaptedto any target family for which
Figure 5. Percentage composition of each ion channel category by number of templates in the ChEMBLﬁltered, CommAvail, and DDU_IC data sets.
Total number of represented templates in each data set in parentheses.
Table 2. Comparison of Example Structures of Bioactive Templates with/without Lead-like Commercial Compounds2453 dx.doi.org/10.1021/ci200260t |J. Chem. Inf. Model. 2011, 51, 2449–2454
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chemical information is available in ChEMBL or other related
databases.
The presence of gaps for ion channel-active compounds in
lead-like commercial chemical space became apparent when
assembling the ion channel library. Only 329 compounds (<5%)
intheChEMBLﬁltereddatasetwerecommerciallyavailablebased
on our in-house database. This is perhaps not surprising, since
many compounds in ChEMBL are retrieved from medicinal
chemistry literature, which often describes hit or lead optimiza-
tion eﬀorts. When searching for lead-like commercially available
compounds
8 using the 297 bioactive templates derived from
MCS (Table 1), compound availability was vastly improved,
although a signiﬁcant proportion of the selected templates
remainedunrepresented(Figure5).Theseunavailabletemplates
are present across all ion channel categories (Table S1 in the
Supporting Information), and many of them do not appear to be
synthetically more challenging thanthe available ones (Table 2).
A similar observation was noted before when we assembled a
focused kinase screening library.
8 The observed absence of ion
channel templates in commercial chemical space is also sup-
portedbyarecentpublicationbyChuprinaetal.whoestimateda
generally low occurrence of prospective ion channel modulators
relative to other target classes from a collection of commercial
chemical suppliers similar to those in our in-house database.
19
Althoughthecollection ofsuppliersinourdatabasemaynotrep-
resenta comprehensivecoverageof the entire commercialchemical
space, our observations here, together with that of Chuprina et al.,
indicatethereisstillscope forcompoundvendorstoincreasethe
diversity of lead-like compounds on oﬀer in their libraries.
’CONCLUSIONS
We have demonstrated an eﬃcient workﬂow to assemble a
focusedscreening libraryforionchannel targets usingbioactivity
data retrieved from ChEMBL. The workﬂow is based on the
eﬃcientminingofanopen-accessdatabasecontainingbioactivity
data for structurally diverse therapeutic target families and
demonstrates an eﬀective solution using bioactive templates to
overcome the problem associated with limited compound avail-
ability. The ﬁnal screening library contained 3241 compounds
representing 123 templates across nine ion channel categories.
These compounds were annotated with their respective ion
channel category to enable eﬃcient back-tracing of prospective
moleculartargetsfromphenotypicscreeningresults.Thescreen-
ing library is currently being used in campaigns to identify new
chemical starting points toward ion channel targets for various
neglected disease programs within the Drug Discovery Unit at
Dundee. These results will oﬀer valuable data to evaluate the
quality of this newly assembled screening library.
’EXPERIMENTAL PROCEDURES
ChEMBLfiltered Data Set. Bioactivity data of compounds
annotated with associated ion channel targets (337 molecular
targets in 14 categories) were retrieved from the ChEMBL
database (accessed Feb 16Mar 4, 2010). All filters applied
were carried out using Pipeline Pilot professional client 7.5
(Accelrys,Inc.).UnwantedgroupsweredescribedasSMARTS
strings,
8 and compounds were matched against the SMARTS
description using substructure mapping.
CommAvailDataSet.StructuralclassesoftheChEMBLfiltered
datasetweregeneratedusingClassPharmer4.7(SimulationsPlus,Inc.).
The criteria of structural classes were
a minimum of 2 rings (either 2 single rings linked together or
1 fused ring),
13 functional groups attached to any ring system,
am a x i m u mo f5b o n d sb e t w e e nar i n ga n daf u n c t i o n a l
group, and
a maximum of 5 bonds between ring-connected fragments.
Under-represented classes were deﬁned as those containing
fewer than ﬁve compounds of which no bioactivities were better
than5μM.Bioactivetemplatesselectedwereannotatedwiththeir
respective ion channel categories. These templates were used as
substructures tosearchfor commerciallyavailablecompoundsin
our in-house database containing ∼5.9 million unique com-
poundsfrom20commercialchemicalsuppliers(asofJune2010).
Compounds in the CommAvail data set were chosen according
to the lead-like criteria as previously described.
8
DDU_IC Data Set. Compound clustering and the selection of
representative examples followed the same procedure as pre-
viously published.
8
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b S Supporting Information. Tables listing the 297 short-
listed bioactive templates used for commercial availability search
and their corresponding SMARTS deﬁnitions. This material is
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